Farrington C P, Miller E
Department of Statistics, Open University, Walton Hall, Milton Keynes MK7 6AA, England.
Mol Biotechnol. 2001 Jan;17(1):43-58. doi: 10.1385/MB:17:1:43.
This article reviews some of the issues involved in evaluating vaccines in humans. Vaccine trials are required for licensure and are essential for demonstrating a vaccine's safety and protective efficacy. The formal framework of phase I, II, and III trials is described, with particular emphasis on the choice of hypotheses, trial design, and biases that arise in the context of vaccine trials. However, some aspects of a vaccine's performance cannot be evaluated in clinical trials owing to their relatively small size. Thus, vaccine evaluation must continue after licensure, for example, to evaluate the vaccine with respect to rare reactions, duration of protection, and ecological effects. The article reviews some of the methods commonly used for post-licensure studies of vaccine efficacy and safety.
本文综述了人体疫苗评估中涉及的一些问题。疫苗试验是获得许可所必需的,对于证明疫苗的安全性和保护效力至关重要。文中描述了I期、II期和III期试验的正式框架,特别强调了假设的选择、试验设计以及疫苗试验中出现的偏差。然而,由于临床试验规模相对较小,疫苗性能的某些方面无法在临床试验中进行评估。因此,疫苗评估在获得许可后仍需继续,例如,评估疫苗在罕见反应、保护持续时间和生态效应方面的情况。本文综述了疫苗效力和安全性上市后研究常用的一些方法。